Log In
BCIQ
Print this Print this
 

INT0024

  Manage Alerts
Collapse Summary General Information
Company IntelGenx Corp.
DescriptionOral tablet using IntelGenx's VersaTab multilayer tablet technology
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today